Intrapulmonary pharmacokinetics of linezolid - Test2 - elhamkhani - TriplyDB

Intrapulmonary pharmacokinetics of linezolid

Intrapulmonary pharmacokinetics of linezolid

http://www.wikidata.org/entity/Q34106719

about

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis Linezolid has unique immunomodulatory effects in post-influenza community acquired MRSA pneumonia Management of community-associated methicillin-resistant Staphylococcus aureus infections in children.A review of linezolid: the first oxazolidinone antibiotic.Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Linezolid for treatment of chronic extensively drug-resistant tuberculosis.The challenge of new drug discovery for tuberculosis.Validation of a new HPLC-UV method for determination of the antibiotic linezolid in human plasma and in bronchoalveolar lavage.Pharmacokinetics and efficacy of linezolid in a gerbil model of Streptococcus pneumoniae-induced acute otitis media.Linezolid for the treatment of drug-resistant infections.Prediction of methicillin-resistant Staphylococcus aureus in patients with non-nosocomial pneumonia.Linezolid pharmacokinetics in adult patients with cystic fibrosis Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients.Antibiotic management of methicillin-resistant Staphylococcus aureus--associated acute pulmonary exacerbations in cystic fibrosis.Pharmacodynamic Profile of GSK2140944 against Methicillin-Resistant Staphylococcus aureus in a Murine Lung Infection Model Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model.Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers.Clinical update on linezolid in the treatment of Gram-positive bacterial infections.Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis.Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia.Hospital-acquired pneumonia in the 21st century: a review of existing treatment options and their impact on patient care.Guidelines for the prevention and management of community-associated methicillin-resistant Staphylococcus aureus: A perspective for Canadian health care practitioners.Linezolid: a new antibiotic for newborns and children?Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus.Vancomycin: does it still have a role as an antistaphylococcal agent?Pharmacokinetics and pharmacodynamics of antibacterial agents.Surgical site infection prophylaxis strategies for cardiothoracic surgery: a decision-analytic model.Interpretation of antibiotic concentration ratios measured in epithelial lining fluid.Linezolid: effectiveness and safety for approved and off-label indications.Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis Healthcare-associated pneumonia: principles and emerging concepts on management.Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults.Pneumonia caused by methicillin-resistant Staphylococcus aureus.Vancomycin resistance: are there better glycopeptides coming?

P2860

Q22241905-39960A21-86BF-41A6-8F0C-6FD87801EA2D Q26852253-15AC39B4-1D27-4C35-BCE1-C9F69A934FD5 Q28542435-01A4D515-D545-4BD4-9BCA-B16DCD605EAD Q28543159-98384D56-3020-4033-A58F-94805A0E1AC6 Q33264579-41521532-EF6A-4748-822E-2FD76074A929 Q33363226-7E910A7D-62D2-4EEE-AD32-B6A878F35ADB Q34157657-C6F5336B-4FAC-4D84-BA51-C238C0645258 Q34644127-B7F20707-58DE-410F-BAEF-AA8F85135469 Q34660424-6A202763-778A-4760-82BD-AD6D274DC510 Q34787394-F487AB4A-424B-4A93-9233-0165B569A882 Q34883537-5092D113-18D3-4E32-A3F1-76BEE052682A Q34894133-375D8CAA-6018-4E8A-AC98-7BBDEA446A37 Q34928386-474D1D8F-6BE6-4DE4-872E-85C1D783DCDB Q35006010-58BCB5C6-FC6E-47A5-903E-89DBA0DAF7E8 Q35215457-93AE315C-45B1-4A03-8F83-7862E5B9A3CC Q35542062-2FB23899-E977-4FB6-9253-3AEC6B631DC2 Q35859914-6BE6C41D-9763-4F10-9CC1-0DF5A90C2300 Q35941253-D468B79B-0F09-435A-8D13-4391F4BB8047 Q35941279-75A40D4C-3AEE-4A0C-9294-6A44A29AEF48 Q36083208-53EE9F28-15CB-4E35-9C22-DB84BE4BB938 Q36172558-962EBB45-80AB-48DD-82CB-40629BAA1851 Q36364009-FF4581B8-2543-41EF-B1A1-B52A7E1B361B Q36364155-27FD770D-BFAB-4076-9BA5-152E5FD64E88 Q36422696-64891CB0-4219-418C-840D-CC5AC8FD0A76 Q36428418-892F296F-5DCD-4C06-A359-69B5F59E030F Q36548708-9FE9CF60-9D83-48F8-BB85-0DBA367A03A3 Q36563779-11E8DFDA-24DD-44E7-A4EC-F2136B225934 Q36724345-B14F1506-BFD4-4100-A0D4-826017E86362 Q36735202-476441D5-7BF2-447E-A96D-84B03F9FCE20 Q36839712-0E287F87-659F-4C9A-975A-E30823DAEE11 Q36911111-E5F03165-C270-4C73-8F54-88F5085AA493 Q36933217-8858CC57-1D11-4465-8850-2D0B488559E0 Q36936597-FBF1BF30-1E2B-4A5F-A127-3A6D933D1CE7 Q36967288-60CF306B-9D1B-49E3-B559-851AAFAF15E2 Q36969745-15B5633A-8677-43B3-B664-2A8C00519AE7 Q36986669-804F1E14-82B3-4449-8EFD-5A93277F8D79 Q37013020-A6A9601B-D579-4FD0-A14D-1BF76F7C9B61 Q37029217-DD6BC120-9346-4DCE-A18C-B5E75F05A684 Q37156705-4C098FA9-DB7B-4677-88C9-0CCA0F43590F Q37340562-54465BCD-D74A-46C5-9DF7-4F8740345BB8

P2860

Intrapulmonary pharmacokinetics of linezolid

http://www.wikidata.org/entity/Q34106719

description

2002 nî lūn-bûn

@nan

2002 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Intrapulmonary pharmacokinetics of linezolid

@ast

Intrapulmonary pharmacokinetics of linezolid

@en

Intrapulmonary pharmacokinetics of linezolid

@nl

type

label

Intrapulmonary pharmacokinetics of linezolid

@ast

Intrapulmonary pharmacokinetics of linezolid

@en

Intrapulmonary pharmacokinetics of linezolid

@nl

prefLabel

Intrapulmonary pharmacokinetics of linezolid

@ast

Intrapulmonary pharmacokinetics of linezolid

@en

Intrapulmonary pharmacokinetics of linezolid

@nl

P1433

Q34106719-7ACAFA31-BCD0-4FE8-BFA9-16550E5A6D9B

P1476

Q34106719-4E6976A5-6C38-43DC-83EC-22209897A3A0

P2093

Q34106719-71D4B020-0978-4890-8B68-F05796579908

Q34106719-78D1A0AD-AE2A-4A76-A86F-E3388BEFC3B9

Q34106719-81CA64C1-E510-487A-93CB-E5139D27A4C5

Q34106719-D980AFC6-CF2C-4A87-9217-BF26BAC86B21

P2860

Q34106719-0F20312E-B9BF-47AB-8DAD-AFB4355E5536

Q34106719-1A28ABDC-0882-43F0-873E-C40CD7255D41

Q34106719-22382AF7-DE25-4FFE-8E0B-4497F42E912A

Q34106719-2380D3E2-83AB-47F5-8570-7036BEFC1E52

Q34106719-24A3D4D7-073E-457B-B8FF-C21B991F4116

Q34106719-2B16E9E2-8B06-4EAF-9DBA-C2DE3E0D6D44

Q34106719-2BA3158B-0C54-444C-8CCB-A8F0240C05D2

Q34106719-3124F900-4A78-455A-BC95-D10DAF88EEFC

Q34106719-318DBDB3-83DB-4E71-90DF-26E7817E26AE

Q34106719-31B304CB-2E81-4AB3-AB0E-45078785EA16

P304

Q34106719-41F111C5-6AE6-43A6-8AF6-7943F9FCEFC9

P31

Q34106719-3621143A-FEF2-4912-83D6-3AB453F43CC5

P356

Q34106719-42214334-8DE4-4B31-A1F7-C909894F0ACC

P407

Q34106719-3A119C0A-9C31-4029-B510-DDF688A4C4A3

P433

Q34106719-4DC1E910-EFB2-4715-A21F-9534F66634F7

P478

Q34106719-3D75A3E5-0384-4B97-9DCD-950A98EC267D

P577

Q34106719-8113C9D6-C9AC-49DC-8D01-AAB5EAF21687

P5875

Q34106719-031BBA30-3C41-45CE-8A38-AE1E591E2C9A

P698

Q34106719-EED322B9-F4A2-433E-80F4-C6D1115C004C

P932

Q34106719-1AACD994-21D5-4DFD-AB53-3C39A142DB6D

P356

AAC.46.5.1475-1480.2002

P1433

Antimicrobial Agents and Chemotherapy

P1476

Intrapulmonary pharmacokinetics of linezolid

@en

P2093

Elisabeth Zurlinden

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Golden

http://www.w3.org/2001/XMLSchema#string

John E Conte

http://www.w3.org/2001/XMLSchema#string

Juliana Kipps

http://www.w3.org/2001/XMLSchema#string

P2860

Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model

Oxazolidinones: a review

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

Intrapulmonary concentrations of pyrazinamide.

In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci

Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects.

In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.

Effects of AIDS and gender on steady-state plasma and intrapulmonary ethionamide concentrations.

Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci.

Activities of linezolid against rapidly growing mycobacteria.

P304

1475-1480

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.46.5.1475-1480.2002

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P577

2002-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11407036

http://www.w3.org/2001/XMLSchema#string

P698

11959585

http://www.w3.org/2001/XMLSchema#string

P932

127139

http://www.w3.org/2001/XMLSchema#string